Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
Want to see CVKD full AI Analyst Report?
CVKD Stock Chart & Stats
$5.22
-$1.27(-7.12%)
At close: 4:00 PM EST
$5.22
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$4.21 - $16.25
Previous CloseN/A
Volume16.20K
Average Volume (3M)57.36K
Market Cap
$14.50M
Enterprise Value$10.36M
Total Cash (Recent Filing)$2.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 06, 2026EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.63
Shares Outstanding2,868,247
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.84K
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$29.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Orphan Designation And Clinical SignalsVLX-1005 holds Orphan Drug Designation and early clinical studies reported safety and interim evidence of reduced thromboembolic events in patients evaluated for suspected heparin‑induced thrombocytopenia, suggesting a differentiated clinical and commercial prospect.
Pipeline Expansion Through AcquisitionsAcquisition of a portfolio of Factor XIa inhibitors significantly expands the company’s anticoagulation pipeline and broadens future therapeutic opportunities beyond existing programs.
Regulatory ProgressRegulatory discussions are helping define a clear path for tecarfarin to advance into late-stage development for patients with end-stage kidney disease and atrial fibrillation.
Bears Say
Acquisition Financial UncertaintyFinancial terms of recent acquisitions were not disclosed, creating uncertainty about the near-term financial impact despite expectations of future milestone payments and royalties.
Cash Runway And Financing RiskThe company finished the reporting period with limited cash and will likely need to secure additional funding to advance programs, otherwise research and development activities may need to be scaled back or delayed.
Valuation And Dilution RiskAnalyst reduced the valuation to reflect an updated share count and anticipated financing needs, indicating potential dilution and downward pressure on the stock.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $4.21 and its highest was $16.25 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $14.50M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 81 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.04.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.55.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,868,247 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.431%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$29.00
▲(455.56% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
13.81% Insiders
2.05% Mutual Funds
0.06% Other Institutional Investors
82.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---